June 6 (Reuters) - The European Medicines Agency's (EMA)
safety committee has concluded that a potentially dangerous eye
condition is a very rare side effect of Novo Nordisk's
popular treatments Ozempic and Wegovy, it said on
Friday.
The condition may affect up to 1 in 10,000 people taking
semaglutide, the chemical name for Wegovy and Ozempic, the EMA
said.